Abstract.
THE
pineal hormone melatonin can inhibit gonadotropin secretion and ovulation in immature [1, 2] as well as in mature female rats [3, 4] . The inhibitory effect of melatonin is partially exerted at the level of the pituitary, since it attenuates luteinizing hormone (LH) release induced by LH-releasing hormone (LHRH) from fetal, neonatal or developing rat pituitaries [5] [6] [7] [8] .
However, the effect of melatonin at the suprapituitary level is controversial, in that melatonin either increased [9, 10] , decreased [10] or did not change [10, 11] LHRH output from the hypothalamus of adult male rats in vitro.
The discrepancy in the reported effects of melatonin in the hypothalamus is due, in part, to the difference in the experimental condition including the time of experiments and the hypothalamic structures involved in the in vitro preparation [10] . These differences would consequently affect hypothalamic neurotransmitter release and receptor activities, which in turn might affect the effect of melatonin. Thus, the mechanism of melatonin action is not simple but may involve complex interactions with other transmitters in the hypothalamus. Among the major transmitters that stimulate gonadotropin secretion are excitatory amino acids including glutamate [12, 13] . Endogenous opioid peptides, such as j3-endorphin, on the other hand, are major inhibitory factors involved in controlling gonadotropin secretion [14, 15] . Therefore, in the present study, we aimed to elucidate the possible functional relationship between melatonin and these transmitters in the control of gonadotropin secretion. For this purpose, we examined the effects of melatonin on luteinizing hormone (LH) release induced by naloxone, a ji opioid receptor antagonist, and by Nmethyl-D-aspartate (NMDA), an excitatory amino acid agonist, in ovariectomized estrogen-primed rats. Melatonin was injected intracerebroventricularly (icy) in order to minimize the direct action of the indoleamine at the pituitary level. The possibility of pituitary melatonin action was further evaluated by examining its effect on LHRH-induced LH release.
Materials and Methods
Materials and methods were similar to those employed in our previous studies [16] [17] [18] . In brief, female rats of the Wistar-Imamichi strain, purchased at the age of 8 weeks, were ovariectomized and housed under artificial light (lights on 0630-1830 h) and temperature control (22-24°C), with free access to laboratory chow and tap water. A guide cannula of stainless steel tubing was placed stereotaxically to the third cerebral ventricle about 3 weeks before the experiment. The rat was primed with a subcutaneous injection of 20 pg estradiol benzoate at noon 3 days before the experiment. An intraatrial cannula of silascone tubing (KM 075017, Kaneka Medix Co., Osaka, Japan) was inserted through the jugular vein under light ether anesthesia on the day before bleeding to facilitate intravenous (iv) injection and sequential blood sampling. Experiments were performed the next morning (0900-1200 h) in freely moving rats. Melatonin (Sigma; 100 ng/2 pl) was suspended in physiological saline with the aid of an ultrasonic mixer, and the suspension was injected icy 60 min before an iv injection of naloxone, NMDA or LHRH. Naloxone (naloxone hydrochloride, Sigma; 10 mg/kg body weight), NMDA (Sigma; 20 mg/kg) and LHRH (Sigma; 50 ng/kg), dissolved in physiological saline, were injected iv through the indwelling cardiac cannula in a volume of 1 ml/kg. The dose of these chemicals was selected based on our preliminary experiments and previous studies [16] [17] [18] . Control injections were made with physiological saline. Blood samples (200 ul each) were collected through the indwelling cardiac cannula without restraining the rat. Animals were bled immediately before and 15 and 60 min after the icy injection of melatonin. Naloxone, NMDA or LHRH was injected iv immediately after the third bleeding (60 min after the melatonin injection). Thereafter, sequential blood samples were obtained at 10 min intervals for 60 min. The same volume of physiological saline was infused through the bleeding cannula after each blood sample. Sera were separated after the centrifugation, and stored frozen at -30°C until assayed. LH concentrations were determined in 50 p1 sera by the competitive radioimmunoassay method following the instructions provided in the NIDDK rat LH radioimmunoassay kit, and were expressed in terms of the NIH-LH-S1.
The intra-and inter-assay coefficients of variation, estimated at the mean LH concentration of 5.53 ng/ml in five replicates of pooled serum, were 5.2% and 6.3%, respectively. Serum LH concentrations were statistically analyzed by two-way analysis of variance followed by Duncan's new multiple range test.
Results
Icy injections of melatonin did not affect serum LH concentrations measured 15 and 60 min after the injection (Figs. 1-4) , suggesting that melatonin did not affect the basal LH secretion by itself. In these rats treated icy with saline or melatonin, subsequent iv injections with saline were without effect on LH secretion (Fig. 1) .
In rats treated with saline, subsequent iv injections with naloxone elevated serum LH concentrations within 10 min (Fig. 2) . The elevated LH level gradually declined thereafter. Naloxone also produced a small but statistically significant increase in the serum LH concentration within 10 min, in rats treated icy with melatonin 60 min before. However, the effect of naloxone was significantly diminished in these melatonin-treated rats, as compared to that in saline-treated rats.
The effects of melatonin on NMDA-induced and LHRH-induced LH release are shown in Figs. 3 and 4, respectively. Iv injections of NMDA or LHRH significantly stimulated LH release, within 10 min, in control animals treated icy with saline. Pretreatment of rats with melatonin affected neither the effect of NMDA nor that of LHRH. Similar results were obtained when melatonin was injected icy 30 min before the iv challenge (data not shown).
Discussion
Elevation in serum LH concentrations after the naloxone injection in saline-treated rats was similar to the results of previous studies including our own [15, [17] [18] [19] . The opioid antagonist is believed to stimulate LH secretion by interrupting the inhibitory action of the endogenous opioid in the hypothalamic LHRH neural network [15, 19] . Stimulation of LH release by NMDA was also consistent with the results of previous studies, which suggest a stimulatory role of excitatory amino acid transmitters, mediated by the NMDA receptor, on LH secretion [12, 13, 16, Fig. 2. Serum LH concentrations in ovariectomized estrogen-primed rats with icy injections with saline or melatonin followed 60 min later by iv injections with naloxone.
Values are means and standard errors of the mean.
Sal: saline. Mel: melatonin. Nal: naloxone.
N=8 in each group. a: p<0.05 vs basal LH at 0 min. b: p <0.05 vs saline-treated rat at the corresponding time. Values are means and standard errors of the mean. Sal: saline. Mel: melatonin.
N=6 and 7 in Sal + NMDA and Mel + NMDA, respectively. a:
p<0.05 vs basal LH at 0min. While previous studies uniformly showed a pituitary site of melatonin action in inhibiting gonadotropin secretion [5] [6] [7] [8] , the hypothalamic actions of the indoleamine still remain debatable [9] [10] [11] . The failure of icy melatonin to affect basal LH secretion in the present study suggests that, under the negative feedback condition in estrogen-primed rats, the indoleamine does not produce further inhibition on the already low LHRH secretion.
We have recently found that an icy treatment with melatonin significantly inhibited LH release induced by an icy injection of naloxone in the ovariectomized estrogen-primed rat [18] . In the present study, icy melatonin was also effective in suppressing LH release induced by an iv injection of naloxone, suggesting that melatonin can inhibit the effect of naloxone regardless of whether the opioid antagonist is administered centrally or peripherally.
On the other hand, the same icy injection of melatonin did not affect LHRH-induced LH release. This proves that the centrally injected melatonin did not diffuse into the portal circulation to a degree sufficient to affect the pituitary responsiveness to LHRH. Decrease in the pituitary melatonin receptors in mature rats [22, 23] might also have contributed to the lack of effect of melatonin at the pituitary level. In any case, it is apparent that melatonin has a suprapituitary site of action to inhibit naloxone-induced LHRH release. The result also suggests that the site of melatonin action may be located downstream to the site of naloxone action, i.e. the site of opioid action, in the hypothalamic LHRH neuronal pathway.
As far as we know, there have been no published studies concerning the relationship between melatonin and excitatory amino acid transmitters in controlling gonadotropin secretion.
In the present study, icy injections of 100 ng melatonin did not affect the NMDA-induced LH secretion at all. The same icy dose of melatonin significantly inhibited the effect of naloxone injected either icy [18] or iv (this study), as described above. Further, the indoleamine was effective at the dose as low as 10 ng in inhibiting LH release induced by the icy naloxone injection [18] . Thus, it is unlikely that the icy dose of melatonin (100 ng) used in this experiment was insufficient. If the site of melatonin action and that of NMDA are organized in parallel, or in a serial arrangement with the former being located downstream to the latter at the suprapituitary level, then the pineal hormone, when given at a sufficient dose, would more or less inhibit the effect of NMDA on LH secretion. Therefore, the simplest explanation for the failure of melatonin to affect NMDA-induced LH release would be that the site of melatonin action is located upstream to that of NMDA action in the hypothalamic LHRH pathway.
Previous studies in our laboratory have shown that an icy injection of 2-amino-5-phosphonovaleric acid, a specific NMDA receptor antagonist, inhibited not only NMDA-induced but also naloxone-induced LH release in ovariectomized estrogen-primed rats [21] . On the other hand, an icy injection of corticotropinreleasing factor inhibited naloxone-induced [17, 21] , but not NMDA-induced [21] , LH release. In addition, j3-endorphin, an endogenous opioid peptide, did not inhibit [21, 24] , but rather facilitated [25] , the effect of NMDA. All of these findings are consistent with the hypothesis that the site of the opioid action is located upstream to the site of the excitatory amino acid action in the hypothalamic LHRH neuronal pathway. The present result that melatonin inhibited naloxone-induced, but not NMDA-induced, LH secretion may suggest that the site of melatonin action is located between the site of opioid action and that of amino acid action in this hypothetical arrangement.
Circulating melatonin concentrations show a nocturnal elevation in the rat [26, 27] . A variety of stress stimuli also increase pineal melatonin secretion during the light period [28] [29] [30] . These changes in melatonin secretion may affect endogenous opioid control of gonadotropin secretion. For example, we have recently shown that both acute immobilization stress [17, 30] and melatonin administration [18 and the present study] inhibited naloxone-induced LH release in female rats. In addition, pinealectomy partially restored the effect of naloxone on LH secretion in rats undergoing the acute immobilization stress [30] . These findings suggest that the pineal hormone may play a physiological role in transmitting stress-related inhibitory signals from the pineal gland to the hypothalamic LHRH regulatory mechanism.
